

PharMerica CORP
Form 8-K
August 02, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 2, 2017

PHARMERICA CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Edgar Filing: PharMerica CORP - Form 8-K

Delaware
(State or Other Jurisdiction of Incorporation)

001-33380
(Commission File Number)

87-0792558
(IRS Employer Identification No.)

1901 Campus Place

Louisville, Kentucky
(Address of principal executive offices)

40299
(Zip Code)

(502) 627-7000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On August 2, 2017, PharMerica Corporation (the “Company”) issued a press release announcing results of operations for the second quarter ended June 30, 2017, a copy of which is attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release of PharMerica Corporation dated August 2, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMERICA CORPORATION

Date: August 2, 2017 By: /s/ Robert E. Dries
Robert E. Dries
Executive Vice President and Chief Financial Officer

Exhibit Index

Exhibit No. Description

99.1 Press Release of PharMerica Corporation dated August 2, 2017.